Board of Governors of the Federal Reserve System, December 20, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99–33382 Filed 12–22–99; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225), to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 10, 2000.

A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. UBS AG, Zurich, Switzerland; to acquire, through its wholly owned indirect subsidiary, North Street Finance LLC, New York, New York, the telephone and answering machine leasing business of Lucent Technologies Consumer Products L.P., Murray Hill, New Jersey, and thereby engage in certain leasing activities, pursuant to § 225.28(b)(3) of Regulation Y.

Board of Governors of the Federal Reserve System, December 20, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99–33383 Filed 12–22–99; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB.

1. Recordkeeping Requirements for Government Owned/Contractor Held Property and Report of Accounting Personal Property (HHS–565)—0990–0015—Extension—The recordkeeping requirements are needed to assure accountability and control for government owned/contractor held property for HHS contracts. Form 565 is used to report all accountable personal property purchased or fabricated by contractors and billed to HHS.

Respondents: State or local governments, business or other for-profit, non-profit institutions, small business;

Burden Information for Form HHS–565:

Annual Number of Respondents: 3,600;

Annual Frequency of Response: One time;

Average Burden per Response: 30 minutes;

Total Annual Burden: 1,800 hours;

Burden Information for Recordkeeping Requirements: Annual;

Number of Responses: 4,500;

Average Burden per Response: 30 minutes;

Total Annual Burden: 2250 hours;

Total Burden: 4050 hours.

OMB Desk Officer: Allison Eydt.

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690–6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street NW, Washington, DC 20503.

Comments may also be sent to Cynthia Ages Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Written comments should be received within 30 days of this notice.

Dated: December 10, 1999.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 99–33262 Filed 12–22–99; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Title: Child Care Annual Aggregate Report.

OMB No.: 0970–0150.

Description: This legislatively mandated report collects program and participant's data on all children and families receiving direct Child Care and Development Fund services. Aggregate data is collected and will be used to determine the scope, type, and methods of child care delivery, and to provide a report to Congress. The revisions in this report are proposed to further clarify existing information upon which the report is based and to provide data for GPRA performance measures.

Respondents: State, local or tribal government.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF–800	56	1	40	2,240

Estimated Total Annual Burden Hours: 2,240.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Resource Management Services, 370 L'Enfant Promenade, SW, Washington, DC 20447, Attn: Reports Clearance Officer. This information collection and an electronic comment form are also available at the following Child Care Bureau Web Site: *http://www.acf.dhhs.gov/programs/ccb/systems/index.htm.*

The Department specifically requests comments on: (a) Whether the proposed revised collection of information is necessary for the proper performance of the functions of the agency; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: December 20, 1999.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 99–33384 Filed 12–22–99; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98D–0969]

Guidance for Industry: Consideration of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals (GFI #78); Availability; Republication

Editorial Note: FR Doc. 99–32324 was originally published at page 70716 in the **Federal Register** of Friday, December 17, 1999. The companion Framework document was inadvertently not published. At the request of the agency, FR Doc. 99–32324 is republished below in its entirety together with the companion Framework document.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a final guidance document entitled ''Guidance for Industry: Consideration of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals'' (GFI #78). After the agency considered public comments on a draft of this guidance, announced in the **Federal Register** of November 18, 1998, it determined that revision of the draft guidance was necessary. GFI #78 addresses how under section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b) FDA intends to consider the potential human health impact of the microbial effects associated with all uses of all classes of antimicrobial new animal drugs intended for use in food-producing animals when approving such drugs. For additional information regarding the subject matter dealt with in GFI #78, see the notice of availability of the document entitled ''FDA Response to Comments on a Proposed Framework for Evaluating and Assuring the Human Food Safety of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals'' that appears elsewhere in this issue of the **Federal Register**.

DATES: Submit comments at any time.

ADDRESSES: Submit written comments on GFI #78 to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1061, 5630 Fishers Lane, Rockville, MD 20852.

FDA will also accept electronic comments. Persons who wish to submit electronic comments should go to the FDA home page at www.fda.gov and select ''Dockets'' and follow the instructions.

Submit written requests for single copies of the document entitled ''Guidance for Industry: Consideration of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals'' (GFI #78) to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests. See section III. Electronic Access of this document for information on electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Sharon Thompson, Center for Veterinary Medicine (HFV–1), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1798, e-mail: sthompso@cvm.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of November 18, 1998 (63 FR 64094), FDA announced the availability of a draft guidance entitled ''Guidance for Industry: Evaluation of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals'' (GFI #78). This draft guidance announced that FDA believed that it is necessary to evaluate the human health impact of the microbial effects associated with all uses of all classes of antimicrobial new animal drugs intended for use in food-producing animals when approving such drugs. The publication of the draft of GFI #78 was the first step in the agency's consideration of the issues related to the use of antimicrobial new animal drugs in food-producing animals. The draft of GFI #78 laid out the agency's rationale for its current thinking about its authority under section 512 of the act to consider the human health impact of the microbial effects associated with the use of antimicrobial new animal drugs in food-producing animals.

In the **Federal Register** of January 6, 1999 (64 FR 887), FDA announced the availability of a discussion paper entitled ''A Proposed Framework for Evaluating and Assuring the Human Safety of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals'' (Framework Document). The Framework Document was the second step in the agency's consideration of issues related to the use of antimicrobial new animal drugs in food-producing animals. FDA made the Framework Document available to the public to initiate discussions with the scientific community and other interested parties on the agency's thinking about appropriate underlying concepts to be used to develop microbial safety policies protective of the public health. The Framework Document is related to GFI #78 in that it sets out a conceptual risk-based framework for evaluating the microbial safety (related to human health impact) of antimicrobial new animal drugs intended for use in food-producing animals.

After considering comments received by the public for both the draft of GFI #78 and the Framework Document, FDA determined that it was necessary to make some revisions to GFI #78. The revisions are intended to make GFI #78